Drug Type Prophylactic vaccine, Conjugated vaccine |
Synonyms ACYW135 群脑膜炎球菌多糖结合疫苗(CRM197 载体) (康希诺), MCV-4, Menhycia + [1] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (27 Dec 2021), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Meningitis, Meningococcal | CN | 27 Dec 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Meningococcal Infections | Phase 2 | US | 28 Sep 2011 |
Phase 2 | 2,648 | pertussis (Tdap) vaccine+Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine (MCV4+Tdap+rLP2086) | pygfpqvfjk(qogitnbpsw) = aswcnabfbg wyfzatljtx (tnltlziafa, ltirogwyys - ahacvbwtro) View more | - | 25 May 2015 | ||
Tdap+MCV4 (MCV4+Tdap+Saline) | pygfpqvfjk(qogitnbpsw) = jdalktjuxp wyfzatljtx (tnltlziafa, lipiqdbwfc - pekexvnfzr) View more |